Pharminent · Daily Brief
FDA approves Beren’s Lembaz for Niemann-Pick disease type C
The FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe, infantile-onset form of Niemann-Pick disease type C live longer.
FDA →FDA approves Roche’s breast cancer pill Wilserdly
The FDA approved Roche’s Wilserdly (giredestrant) for ER-positive, ESR1-mutated advanced breast cancer. Analysts described the U.S. approval as a “key first step” in the launch, and Roche has said the drug could become its top-selling product.
BioPharma Dive →$RHHBYWhite House withdraws Heidi Overton’s FDA commissioner nomination
The White House rescinded its nomination of Heidi Overton to serve as FDA Commissioner.
STAT →FDA launches Global Reliance Disclosure Program for drug approvals
The FDA announced the Global Reliance Disclosure Program (GRDP), an initiative to change how the agency’s drug and biologic approval decisions are used by health authorities around the world.
FDA →FDA approves Cosentyx for polymyalgia rheumatica
The FDA approved Cosentyx for polymyalgia rheumatica.
PharmExec →HHS updates HIPAA privacy rule on patient record access
The federal health department updated the HIPAA privacy rule with a focus on supporting patients’ access to their own medical records, setting standards for sharing records with apps.
STAT →Lilly signs cancer deal with Stipple Bio worth up to $5.9B
Eli Lilly entered a cancer partnership with Stipple Bio worth up to $5.9 billion. Stipple plans to start a Phase 1 trial of an antibody-drug conjugate for solid tumors in early 2027.
Pharmaceutical Technology →$LLYGilead signs royalty-free licensing deals for obeldesivir access
Gilead signed royalty-free licensing agreements intended to broaden access to its antiviral obeldesivir.
PharmExec →$GILDIsomorphic Labs raises $5B in Series C financing
Isomorphic Labs raised $5 billion in a Series C financing round to support development of its AI platform and advance its therapeutic candidates toward clinical evaluation.
Pharmaceutical Technology →Marrow Therapeutics launches with $173M for blood disorder drugs
Marrow Therapeutics emerged with $173 million to develop transferrin receptor-targeted “Trojan horse” delivery of medicines for blood disorders, with sickle cell disease and beta thalassemia as its lead indications. Company executives said manufacturing and dosing advantages could make its medicine more broadly accessible worldwide.
MedCity News →Teladoc launches employer contribution option for GLP-1 drugs
Teladoc launched an offering that allows employers to contribute toward the cost of GLP-1 medications.
MedCity News →Pfizer’s CEO says China will be major competition by 2030
Pfizer CEO Albert Bourla said China will be his major competition by 2030, a month after the Chinese government unveiled a five-year biomedical plan to grow its pharmaceutical exports.
Pharmaceutical Technology →$PFEGet the signal in your inbox
Sign up free →Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.